Next Thursday, January 21st, at 2 PM Eastern, HDSA will be hosting an Ask the Doctor Anything webinar. Register today to interact with expert HD physicians Dr. Veronica Santini and Dr. Sharon Sha from our HDSA Center of Excellence at Stanford University, who will answer your HD medical questions live.
Learn More About the PROOF-HD Study of Pridopidine
In late 2020, a company called Prilenia Therapeutics began a large Phase 3 clinical trial of their drug pridopidine. This study builds on a previous study of pridopidine in HD, which did not meet its key clinical goals. However, the drug showed some promise for helping people with HD to maintain their daily functions, an outcome that has recently been accepted by regulatory agencies like the FDA. For this reason, pridopidine is now be tested for longer in a larger group of people. CheckRare released a brief video interview with Dr. Michael Hayden, CEO of Prilenia, in which he talks more about the new trial, called PROOF-HD.
HDSA will also be hosting a research webinar to share further information about PROOF-HD, at 12 PM Eastern on Wednesday, January 27th. Dr. Sandra Kostyk and Dr. Andrew Feigin, expert HD neurologists and PROOF-HD study leaders, will talk more about the trial and what it means for the HD community. You can register to attend here.
PROOF-HD will enroll 480 participants aged 25 or older who have been diagnosed with HD. Participants will take pridopidine for up to 65 weeks by mouth. There will be around 60 study centers in the U.S., Canada and Europe, and active sites are currently listed at www.hdtrialfinder.org and at https://clinicaltrials.gov/ct2/show/NCT04556656. Further details can be found here on the Huntington Study Group’s website.
